

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| Administration | Dosage | Frequency | Description | References | ||
| Mice | D1R-mediated kindling model | Intraperitoneal injection | 5 mg/kg | Administered 30 min prior to each SKF81297 injection, observed for 45 min | Evaluate the effects of JMV-2959 on seizures in the D1R-mediated kindling model, showing no differences in seizure severity and number. | Int J Mol Sci. 2019 May 20;20(10):2480 |
| Rats | Conditioned place preference (CPP), intravenous self-administration (IVSA), and behavioral stimulation models | Intraperitoneal injection | 1 or 3 mg/kg | Single or repeated administration, lasting for 8 days (CPP) or 3 days (IVSA) | JMV2959 significantly and dose-dependently reduced THC-induced conditioned place preference and behavioral stimulation, as well as WIN55,212-2 intravenous self-administration and relapse-like behavior | Int J Mol Sci. 2021 Feb 27;22(5):2397 |
| Rats | Conditioned place preference (CPP) and intravenous self-administration (IVSA) models | Intraperitoneal injection | 1, 3, and 6 mg/kg | Single or multiple administrations, experiments conducted 20 minutes after each administration | JMV2959 significantly reduced methamphetamine-induced conditioned place preference (CPP) expression and decreased methamphetamine intravenous self-administration (IVSA) and relapse-like behavior. | Int J Mol Sci. 2018 Sep 26;19(10):2925 |
| Rats | Opioid-induced changes in dopamine, endocannabinoids, and GABA concentrations in the nucleus accumbens shell model | Intraperitoneal, VTA injection, or NAC perfusion | 3 mg/kg (i.p.) or 2 µg/10 µg (VTA) or 8 mM/40 mM (NAC perfusion) | Single administration, monitored for 3 hours | JMV2959 pre-treatment significantly reversed fentanyl-induced anandamide increases in the NACSh, resulting in a significant AEA decrease and intensified fentanyl-induced decreases in accumbens 2-AG levels, while also reducing fentanyl-evoked GABA efflux and behavioral stimulation. | Int J Mol Sci. 2017 Nov 22;18(11):2486 |
| Rat | Wistar rats | Intraperitoneal injection | 3 mg/kg | Single administration | To investigate the effects of JMV2959 on WIN55,212-2-induced behavioral stimulation and dopamine release in the nucleus accumbens. Results showed that JMV2959 significantly reduced WIN55,212-2-induced behavioral stimulation and dopamine release in the nucleus accumbens. | Int J Mol Sci. 2020 Dec 28;22(1):210 |
| Mice and rats | Alcohol dependence models | Intraperitoneal injection | 9 mg/kg (mice) and 1, 2, 4 mg/kg (rats) | Once daily for 5 days (mice) and twice weekly for 7 days (rats) | JMV2959 reduced ethanol intake but did not affect ethanol preference. In rats, JMV2959 reduced operant self-administration of both ethanol and sucrose. | Neuropharmacology. 2015 Oct;97:182-93 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.83mL 0.37mL 0.18mL |
9.17mL 1.83mL 0.92mL |
18.35mL 3.67mL 1.83mL |
|
| CAS号 | 2448414-54-6 |
| 分子式 | C30H33ClN6O2 |
| 分子量 | 545.08 |
| SMILES Code | O=C(N[C@@H](C1=NN=C(CCC2=CC=CC=C2)N1CC3=CC=C(OC)C=C3)CC4=CNC5=C4C=CC=C5)CN.[H]Cl |
| MDL No. | MFCD31715444 |
| 别名 | |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, 2-8°C |
| 溶解方案 |
DMSO: 250 mg/mL(458.65 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 25 mg/mL(45.87 mM),配合低频超声助溶 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1